التفاصيل البيبلوغرافية
| العنوان: |
Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study |
| المؤلفون: |
Lucila Nassif Kerbauy (10445524), Simrit Parmar (293258), José Mauro Kutner (6327764), Breno Moreno de Gusmão (10445527), Nelson Hamerschlak (624972) |
| سنة النشر: |
2016 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Medicine, Multiple myeloma, Hematology, Physician's practice patterns, Evidence-based medicine, Evidence-based practice |
| الوصف: |
CONTEXT AND OBJECTIVE: For the last nine years, hematologists and oncologists have gathered annually at an educational symposium organized by a Brazilian and an American hospital. During the 2015 Board Review, a survey among the attendees evaluated the differences in management and treatment methods for multiple myeloma (MM). DESIGN AND SETTING: Cross-sectional study during an educational hematology symposium in São Paulo, Brazil. METHODS: Hematologists present at the symposium gave responses to an electronic survey by means of mobile phone. RESULTS: Among the 350 attendees, 217 answered the questionnaire. Most of the participants believed that immunotargeting agents (iTA) might be effective for slowing MM progression in heavily pretreated patients (67%) and that continued exposure to therapy might lead to emergence of resistant clones in patients with MM (76%). Most of the physicians use maintenance therapy after hematopoietic stem cell transplantation (95%) and 45% of them would further restrict it to post-transplantation patients with underlying high-risk disease. The first-line drugs used for transplantation-ineligible patients (TI-MM) were bortezomib-thalidomide-dexamethasone (31%), bortezomib-dexamethasone (28%), lenalidomide-dexamethasone (Rd; 17%) and melphalan-based therapy (10%). Lenalidomide was the drug of choice for post-transplantation maintenance for half of the participants. No significant differences were observed regarding age or length of experience. CONCLUSION: The treatment choices for TI-MM patients were highly heterogenous and the melphalan-based regimen represented only 10% of the first-line options. Use of maintenance therapy after transplantation was a common choice. Some results from the survey were divergent from the evidence in the literature. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/Hematological_approaches_to_multiple_myeloma_trends_from_a_Brazilian_subset_of_hematologists_A_cross-sectional_study/14306272Test |
| DOI: |
10.6084/m9.figshare.14306272.v1 |
| الإتاحة: |
https://doi.org/10.6084/m9.figshare.14306272.v1Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.596BA8A2 |
| قاعدة البيانات: |
BASE |
